Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY
Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-α
K. Lea Sewell, Richard S. Geary, Brenda F. Baker, Josephine M. Glover, Timothy G. K. Mant, Rosie Z. Yu, Joseph A. Tami and F. Andrew Dorr
Journal of Pharmacology and Experimental Therapeutics December 2002, 303 (3) 1334-1343; DOI: https://doi.org/10.1124/jpet.102.036749
K. Lea Sewell
1
2
Richard S. Geary
1
2
Brenda F. Baker
1
2
Josephine M. Glover
1
2
Timothy G. K. Mant
1
2
Rosie Z. Yu
1
2
Joseph A. Tami
1
2
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Journal of Pharmacology and Experimental Therapeutics
Vol. 303, Issue 3
1 Dec 2002
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY
Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-α
K. Lea Sewell, Richard S. Geary, Brenda F. Baker, Josephine M. Glover, Timothy G. K. Mant, Rosie Z. Yu, Joseph A. Tami and F. Andrew Dorr
Journal of Pharmacology and Experimental Therapeutics December 1, 2002, 303 (3) 1334-1343; DOI: https://doi.org/10.1124/jpet.102.036749
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY
Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-α
K. Lea Sewell, Richard S. Geary, Brenda F. Baker, Josephine M. Glover, Timothy G. K. Mant, Rosie Z. Yu, Joseph A. Tami and F. Andrew Dorr
Journal of Pharmacology and Experimental Therapeutics December 1, 2002, 303 (3) 1334-1343; DOI: https://doi.org/10.1124/jpet.102.036749
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement